肿瘤坏死因子拮抗剂治疗失败后的二线生物制剂治疗:一项真实世界倾向评分加权分析
本研究基于两个电子健康记录队列(MSHS与SPARC),比较克罗恩病和溃疡性结肠炎患者在肿瘤坏死因子拮抗剂暴露后换用乌司奴单抗、维得利珠单抗或第二种肿瘤坏死因子拮抗剂的疗效。主要结局为治疗失败复合终点。在克罗恩病中,SPARC队列显示乌司奴单抗较维得利珠单抗显著降低治疗失败风险(调整后风险比0.66,95%置信区间0.54-0.82,P<0.001),MSHS队列呈相同趋势但未达统计学显著;溃疡性结肠炎中二线治疗组间无差异。
要点
- 克罗恩病患者中,SPARC队列显示二线乌司奴单抗较维得利珠单抗显著降低治疗失败风险(调整后风险比0.66)。
- MSHS队列中乌司奴单抗较维得利珠单抗的治疗失败风险呈相同趋势但未达统计学显著(调整后风险比0.89,95%置信区间0.77-1.04,P=0.15)。
- 溃疡性结肠炎患者中,二线治疗组间未发现差异。
核心结论
- 在两个独立真实世界队列中,克罗恩病患者肿瘤坏死因子拮抗剂治疗失败后,二线乌司奴单抗治疗较二线维得利珠单抗与更低的治疗失败可能性相关。
研究设计与样本
- 基于两个电子健康记录队列的真实世界倾向评分加权分析:MSHS队列(克罗恩病527例,溃疡性结肠炎165例)和SPARC队列(克罗恩病412例,溃疡性结肠炎129例)。
- 纳入既往暴露于肿瘤坏死因子拮抗剂并换用不同生物制剂的患者。
- 治疗失败定义为任何IBD相关手术、IBD相关住院、新处方口服/静脉糖皮质激素或需换用第三种生物制剂的复合终点。
- 采用逆概率治疗加权数据进行时间至事件分析。
主要发现
- 总体治疗失败发生于85%的MSHS队列和72%的SPARC队列克罗恩病患者。
- SPARC队列中,二线乌司奴单抗较维得利珠单抗的治疗失败可能性显著更低(调整后风险比0.66,95%置信区间0.54-0.82,P<0.001)。
- MSHS队列中,二线乌司奴单抗较维得利珠单抗的治疗失败风险呈相同趋势但未达统计学显著(调整后风险比0.89,95%置信区间0.77-1.04,P=0.15)。
- 在两个队列中,当治疗失败定义为处方糖皮质激素或第三种生物制剂时,均显示乌司奴单抗较维得利珠单抗的优越性。
- 溃疡性结肠炎中,二线治疗组间未发现差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND& AIMS: Tumor necrosis factor (TNF) antagonists often are used as first-line medications to treat moderate to severe inflammatory bowel disease (IBD), but many patients do not achieve or maintain response. Our aim was to compare the effectiveness of second-line treatments (ustekinumab, vedolizumab, or a second TNF antagonist) after TNF antagonist exposure in patients with Crohn's disease (CD) and ulcerative colitis (UC) from 2 electronic health records-based cohorts. METHODS: We identified patients with prior TNF antagonist exposure who switched to a different biologic in the Mount Sinai Health System (MSHS) electronic health records (CD, n = 527; UC, n = 165) and the Study of a Prospective Adult Research Cohort (SPARC) from the Inflammatory Bowel Disease Plexus Program of the Crohn's & Colitis Foundation (CD, n = 412; UC, n = 129). Treatment failure was defined as the composite of any IBD-related surgery, IBD-related hospitalization, new prescription of oral/intravenous corticosteroids, or need to switch to a third biologic agent. Time-to-event analysis was conducted with inverse probability of treatment-weighted data. RESULTS: Overall, treatment failure occurred in 85% of MSHS and 72% of SPARC CD patients. In SPARC, the likelihood of treatment failure was significantly lower with ustekinumab compared with vedolizumab as second-line treatment (adjusted hazard ratio, 0.66; 95% CI, 0.54-0.82; P < .001), a trend confirmed in MSHS (adjusted hazard ratio, 0.89; 95% CI, 0.77-1.04; P = .15). In both cohorts, the superiority of ustekinumab compared with vedolizumab was shown when considering treatment failure as prescription of steroids or a third biologic agent. In UC, no differences between second-line treatment groups were identified. CONCLUSIONS: In 2 independent real-world cohort settings, second-line therapy in CD with ustekinumab after TNF antagonist treatment failure was associated with a lower likelihood of treatment failure than second-line vedolizumab.
引用
- Ibing S, Cho JH, Böttinger EP, et al. Second-Line Biologic Therapy Following Tumor Necrosis Factor Antagonist Failure: A Real-World Propensity Score-Weighted Analysis. Clin Gastroenterol Hepatol. 2023. PMID: 36787837. doi:10.1016/j.cgh.2023.01.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。